# A Crossover Study to Evaluate the Safety, Tolerability and Efficacy of XPF-002 in Subjects With Postherpetic Neuralgia (PHN)

> **NCT01195636** · PHASE2 · COMPLETED · sponsor: **Xenon Pharmaceuticals Inc.** · enrollment: 70 (actual)

## Conditions studied

- Postherpetic Neuralgia

## Interventions

- **DRUG:** XPF-002
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01195636
- **Lead sponsor:** Xenon Pharmaceuticals Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-08
- **Primary completion:** 2011-03
- **Final completion:** 2011-03
- **Target enrollment:** 70 (ACTUAL)
- **Last updated:** 2013-11-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01195636

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01195636, "A Crossover Study to Evaluate the Safety, Tolerability and Efficacy of XPF-002 in Subjects With Postherpetic Neuralgia (PHN)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01195636. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*